Markers associated with adverse reactions during peanut oral food challenge after peanut oral immunotherapy
FDA-approved peanut oral immunotherapy (pOIT) is a novel peanut allergy therapy to achieve higher allergen reaction threshold. However, pOIT also increases the risk of allergic reactions during therapy. Peanut allergen powder includes peanut subtypes Ara h1, Ara h2, and Ara h6. We hypothesized that patients who failed plain peanut oral food challenge (pOFC) after pOIT may have higher IgE levels of certain peanut allergen subtypes.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Erin Kim, Bryce Binstadt, Nancy Ott Source Type: research